Core Insights - ServiceNow reported quarterly earnings of $4.82 per share, exceeding the Zacks Consensus Estimate of $4.21 per share, and up from $3.72 per share a year ago [1] - The earnings surprise was +14.49%, and the company has surpassed consensus EPS estimates in all four quarters over the past year [2] - Revenues for the quarter reached $3.41 billion, surpassing the Zacks Consensus Estimate by 1.66%, and up from $2.8 billion year-over-year [3] Earnings Performance - The company has consistently exceeded earnings expectations, with a surprise of +15.54% in the previous quarter [2] - The current consensus EPS estimate for the upcoming quarter is $4.40, with expected revenues of $3.5 billion, and for the current fiscal year, the estimate is $16.82 on $13.16 billion in revenues [8] Market Position - ServiceNow shares have underperformed the market, losing about 11.5% since the beginning of the year, while the S&P 500 has gained 17.2% [4] - The Zacks Rank for ServiceNow is currently 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Context - The Computers - IT Services industry, to which ServiceNow belongs, is currently in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9] - Another company in the same industry, Wix.com, is expected to report quarterly earnings of $1.45 per share, reflecting a year-over-year change of -3.3% [10]

分组1 - DaVita HealthCare reported quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $3.29 per share, and showing a decrease from $2.59 per share a year ago, resulting in an earnings surprise of -23.71% [1] - The company posted revenues of $3.42 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.51%, and an increase from $3.26 billion year-over-year [2] - DaVita HealthCare has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 13.3% since the beginning of the year, compared to the S&P 500's gain of 17.2% [3] - The current consensus EPS estimate for the coming quarter is $2.80 on revenues of $3.44 billion, and for the current fiscal year, it is $10.93 on revenues of $13.46 billion [7] - The Zacks Industry Rank for Medical - Outpatient and Home Healthcare is in the top 16% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Viewpoint - TTM Technologies (TTMI) reported quarterly earnings of $0.67 per share, exceeding the Zacks Consensus Estimate of $0.61 per share, and showing a significant increase from $0.41 per share a year ago, indicating strong performance in the printed circuit board sector [1][2]. Financial Performance - The company achieved revenues of $752.74 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.63% and reflecting a year-over-year increase from $616.54 million [2]. - TTM has consistently outperformed consensus EPS estimates over the last four quarters, with an earnings surprise of +9.84% in the latest report and +11.54% in the previous quarter [1][2]. Stock Performance - TTM shares have increased approximately 139.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3]. - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for continued outperformance in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.63, with projected revenues of $726.44 million, and for the current fiscal year, the estimates are $2.32 EPS on $2.82 billion in revenues [7]. - The trend of estimate revisions for TTM has been favorable leading up to the earnings release, suggesting positive sentiment among analysts [6]. Industry Context - TTM operates within the Zacks Electronics - Miscellaneous Components industry, which is currently ranked in the top 13% of over 250 Zacks industries, indicating a strong industry outlook [8]. - The performance of TTM's stock may also be influenced by the overall industry trends, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8].

Core Viewpoint - AtriCure reported a quarterly loss of $0.01 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.11, marking an earnings surprise of +90.91% [1] - The company achieved revenues of $134.27 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.09% and showing a year-over-year increase from $115.91 million [2] Financial Performance - AtriCure has surpassed consensus EPS estimates in all four of the last quarters [2] - The company has also topped consensus revenue estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $139.15 million, and for the current fiscal year, it is -$0.35 on revenues of $530.41 million [7] Stock Performance - AtriCure shares have increased approximately 19.3% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact AtriCure's stock performance [5]

分组1 - Verano Holdings Corp. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, representing an earnings surprise of -140.00% [1] - The company posted revenues of $202.81 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.1%, and down from $216.68 million a year ago [2] - Over the last four quarters, Verano has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] 分组2 - The stock has added about 7.6% since the beginning of the year, underperforming the S&P 500's gain of 17.2% [3] - The current consensus EPS estimate for the coming quarter is -$0.04 on revenues of $207.18 million, and -$0.17 on revenues of $823.1 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Vita Coco Company, Inc. (COCO) reported quarterly earnings of $0.4 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and showing an increase from $0.32 per share a year ago, resulting in an earnings surprise of +25.00% [1] - The company achieved revenues of $182.31 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 14.82% and increasing from $132.91 million year-over-year [2] - The stock has gained approximately 14.4% since the beginning of the year, while the S&P 500 has increased by 17.2% [3] Earnings Performance - Over the last four quarters, the company has consistently surpassed consensus EPS estimates [2] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $130.38 million, and for the current fiscal year, it is $1.15 on revenues of $585.18 million [7] Market Outlook - The company's stock is currently rated Zacks Rank 5 (Strong Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions prior to the earnings release [6] - The Beverages - Soft drinks industry, to which Vita Coco belongs, is ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - Reynolds Consumer Products reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.39 per share, and showing a slight increase from $0.41 per share a year ago, resulting in an earnings surprise of +7.69% [1] - The company achieved revenues of $931 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.60% and reflecting a year-over-year increase from $910 million [2] - The stock has underperformed the market, losing approximately 12.2% since the beginning of the year, while the S&P 500 has gained 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.55 on revenues of $992.49 million, and for the current fiscal year, it is $1.57 on revenues of $3.65 billion [7] - The estimate revisions trend for Reynolds Consumer Products was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Consumer Products - Discretionary industry is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Ionis Pharmaceuticals reported a quarterly loss of $0.61 per share, which was better than the Zacks Consensus Estimate of a loss of $1.15, representing an earnings surprise of +46.96% [1] - The company posted revenues of $157 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 21.23%, and showing an increase from $134 million in the same quarter last year [2] - Ionis Pharmaceuticals has surpassed consensus EPS estimates and revenue estimates for four consecutive quarters [2] 分组2 - The stock has gained approximately 110.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.18 on revenues of $141.77 million, and for the current fiscal year, it is -$2.10 on revenues of $857.58 million [7] - The Medical - Drugs industry, to which Ionis Pharmaceuticals belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - ProPetro Holding reported a quarterly loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a loss of $0.11, indicating an earnings surprise of +81.82% [1] Financial Performance - ProPetro's revenues for the quarter ended September 2025 were $293.92 million, exceeding the Zacks Consensus Estimate by 14.02%, but down from $360.87 million year-over-year [2] - The company has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times in the same period [2] Stock Performance and Outlook - ProPetro shares have declined approximately 21.8% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at -$0.15 for the upcoming quarter and -$0.22 for the current fiscal year [7] Industry Context - The Oil and Gas - Field Services industry, to which ProPetro belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] - The performance of ProPetro's stock may also be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]

Core Viewpoint - Penske Automotive reported quarterly earnings of $3.23 per share, missing the Zacks Consensus Estimate of $3.48 per share, representing a -7.18% earnings surprise [1]. Financial Performance - The company posted revenues of $7.7 billion for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.58%, compared to $7.59 billion in the same quarter last year [2]. - Over the last four quarters, Penske has surpassed consensus EPS estimates three times and topped revenue estimates two times [2]. Stock Performance - Penske shares have increased by approximately 7% since the beginning of the year, while the S&P 500 has gained 17.2% [3]. - The stock currently holds a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.45 on revenues of $7.63 billion, and for the current fiscal year, it is $14.10 on revenues of $30.67 billion [7]. - The trend of estimate revisions for Penske was unfavorable prior to the earnings release, which may impact future stock performance [6]. Industry Context - The Automotive - Retail and Whole Sales industry is currently ranked in the bottom 24% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [8].